Myeloma
SWOG Phase III Newly Diagnosed Multiple Myeloma Trial (S0232) Closed and Patients Given Choice to Switch to REVLIMID Plus Dexamethasone
Published in Blood Weekly, May 31st, 2007
Celgene Corporation (NASDAQ:CELG) announced that the Southwest Oncology Group (SWOG) has permanently closed enrollment in a federally funded clinical trial. The Phase III randomized controlled study (S0232) compared a standard drug therapy, dexamethasone, with a combined therapy of dexamethasone plus REVLIMID (lenalidomide) for patients newly diagnosed with multiple myeloma. Additionally, SWOG announced that current participants in the SWOG study, S0232, be given the choice of switching to REVLIMID with dexamethasone. The SWOG data and safety monitoring committee based its recommendation to permanently close enrollment on the preliminary one year survival results from the Eastern...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2007-05-31)
More Articles from Blood Weekly
- Cardiology
Clinical Guidelines for Blood Conservation During Cardiac Procedures Developed - Hepatitis C Virus
Cure for Hepatitis C Announced by VCU researcher - Angiology
Actilyse (alteplase) recommended by National Institute for Health and Clinical Excellence for treatment of acute ischaemic stroke - Artificial Organs
HepaLife Completes Private Placement for $2.5 Million - Cancer
Cougar Biotechnology Announces Additions to Clinical Research and Development Team - Coagulation
HemoSense to Supply LabCorp with INRatio System - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
